Well-known biomarkers in neuro-oncology include demographic features (such as age) and tumour features (such as grade and O6-methylguanine-DNA methyltransferase [MGMT] promoter methylation status), while imaging biomarkers are used for diagnosis, prognosis, and treatment response monitoring. The gene discussed is MGMT; the disease is neoplasm.